| 3 -0.27 (-8.26%) | 12-01 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 5.24 | 1-year : | 6.12 |
| Resists | First : | 4.48 | Second : | 5.24 |
| Pivot price | 0.89 |
|||
| Supports | First : | 1.83 | Second : | 0.2 |
| MAs | MA(5) : | 2.13 |
MA(20) : | 0.74 |
| MA(100) : | 0.45 |
MA(250) : | 0.79 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 74.4 |
D(3) : | 58.3 |
| RSI | RSI(14): 76.8 |
|||
| 52-week | High : | 4.48 | Low : | 0.2 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ IBIO ] has closed below upper band by 8.3%. Bollinger Bands are 1855.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.14 - 3.16 | 3.16 - 3.17 |
| Low: | 2.76 - 2.78 | 2.78 - 2.8 |
| Close: | 2.97 - 3 | 3 - 3.03 |
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
Fri, 01 Dec 2023
Is Ibio Inc (IBIO) Stock Worth a Buy Friday? - InvestorsObserver
Tue, 28 Nov 2023
Why SenesTech Shares Are Trading Lower By Around 50%? Here ... - Investing.com UK
Mon, 27 Nov 2023
iBio Announces Reverse Stock Split - Yahoo Finance
Thu, 16 Nov 2023
Virus-Like Particle Vaccine Market Latest Report 2023-2031 ... - GlobeNewswire
Wed, 15 Nov 2023
Impact Biomedical Inc. Files Current Report on Form 8-K - Yahoo Finance
Wed, 25 Oct 2023
iBio Inc. stock outperforms market despite losses on the day - MarketWatch
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|